Reference health

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

https://doi.org/10.1177/1352458514556296
CiteStamped reference-health badge
40/40 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

The 40 checked references that resolve
resolves10.1038/356063a0
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
resolves10.1001/archneur.65.12.noc80051
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
resolves10.1002/ana.20858
Immune surveillance in multiple sclerosis patients treated with natalizumab
resolves10.1212/WNL.0b013e3182a84101
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis
resolves10.1182/blood-2007-10-120329
The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
resolves10.1212/01.wnl.0000327671.91357.96
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
resolves10.1002/eji.201142108
Natalizumab treatment perturbs memory‐ and marginal zone‐like B‐cell homing in secondary lymphoid organs in multiple sclerosis
resolves10.1001/archneurol.2011.238
Natalizumab and Impedance of the Homing of CD34<sup>+</sup> Hematopoietic Progenitors
resolves10.1038/bmt.2009.381
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function
resolves10.1007/978-1-4615-2930-9_65
Interaction Through the Lfa-1/Icam-1 Pathway Prevents Programmed Cell Death of Germinal Center B Cells
resolves10.1056/NEJMoa1107829
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
resolves10.1001/archneurol.2010.161
Natalizumab and Progressive Multifocal Leukoencephalopathy
resolves10.1093/cid/cit376
Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
resolves10.1136/jnnp-2012-304332
Changes to anti-JCV antibody levels in a Swedish national MS cohort
resolves10.1177/1352458513477229
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients
resolves10.1177/1352458514538111
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study
resolves10.1177/1352458512463483
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
resolves10.1002/ana.24153
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy
resolves10.1177/000456329002700504
Isoelectric Focusing of Cerebrospinal Fluid Immunoglobulin G: An Annotated Update
resolves10.1136/jnnp.57.8.897
Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.
resolves10.1016/S0022-510X(00)00501-3
Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs
resolves10.1177/135245859800400304
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis
resolves10.1136/mp.48.2.M93
Differential expression of cell adhesion molecules in the functional compartments of lymph nodes and tonsils
resolves10.1056/NEJMe020157
α<sub>4</sub>Integrins as Therapeutic Targets in Autoimmune Disease
resolves10.4049/jimmunol.152.8.3760
Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells.
resolves10.1111/j.1750-3639.2004.tb00049.x
Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis
resolves10.1016/j.jneuroim.2011.03.001
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells
resolves10.1016/j.jneuroim.2007.11.007
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
resolves10.1177/1352458514524998
MiR-126: a novel route for natalizumab action?
resolves10.1128/JVI.03221-13
Lymphocyte Gene Expression and JC Virus Noncoding Control Region Sequences Are Linked with the Risk of Progressive Multifocal Leukoencephalopathy
resolves10.1016/j.jneuroim.2008.05.007
Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
resolves10.1177/1352458510385834
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus
resolves10.1001/jamaneurol.2014.63
JC Virus in CD34<sup>+</sup>and CD19<sup>+</sup>Cells in Patients With Multiple Sclerosis Treated With Natalizumab
resolves10.1002/ana.24148
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis
resolves10.1016/j.jneuroim.2011.02.010
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients
resolves10.1093/infdis/jir256
Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
resolves10.1093/infdis/jir198
Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity
resolves10.1111/j.1750-3639.2011.00538.x
Frequency and Large T (LT) Sequence of JC Polyomavirus DNA in Oligodendrocytes, Astrocytes and Granular Cells in Non‐PML Brain
resolves10.1371/journal.ppat.1004084
JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants
resolves10.1212/WNL.82.10_supplement.S31.004
B Cell-Specific Signal In Whole Blood And Serum Of Natalizumab-Treated PML Patients Is Revealed Using Transcript And Protein Profiling (S31.004)
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1177/1352458514556296"><img src="https://citestamp.com/citestamped/10.1177/1352458514556296/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1177/1352458514556296/badge.svg)](https://citestamp.com/citestamped/10.1177/1352458514556296)